top of page
One in 10 people suffer from one or several of the 80 distinct chronic autoimmune diseases,
or immune-mediated inflammatory diseases (IMIDs).
These include the more common plaque psoriasis, rheumatoid arthritis and Crohn's disease but also
orphan autoimmune diseases, like systemic sclerosis, SLE and sarcoidosis.
There is a clear unmet medical need with the available drug treatments failing to successfully achieve
disease remission quickly after the onset and diagnosis of autoimmune diseases.
OUR INNOVATIVE TECHNOLOGY
The 1st line, cornerstone drug treatment used to treat several autoimmune diseases is methotrexate (MTX). This drug has held on to this place as first choice, because of its good safety profile.
However, MTX as a mono-therapy leads to disease remission in only in about 1/3 of the patients.
In the vast majority of the patients, other drugs (DMARDs) need to be added in order to control the distructive, progressive nature of autoimmune diseases.
The reason for treatment failure with MTX may well be due to poor retention of the drug in the pro-inflammatory cells.
With Amplio Pharma's proprietary NovoBioMed technology we effectively trap drugs at the target, so a lower overall drug dose may result in faster and better efficacy.
With our innovative and insightful technology, we strive to enhance patients’ every day quality of life.
Home: Quote
Home: Our Technology
Home: Contact
GET IN TOUCH
Amplio Pharma BV
Hulstweg 11, PB1
1032 LB Amsterdam, the Netherlands
©2020 by Amplio Pharma B.V.
bottom of page